Global Preimplantation Genetic Testing Market 2026–2034: Size, Share & Growth Drivers

The global Preimplantation Genetic Testing (PGT) market is witnessing robust growth, driven by the increasing demand for advanced reproductive technologies and the rising prevalence of genetic disorders. As assisted reproductive techniques such as IVF (in vitro fertilization) become more mainstream, PGT has emerged as a crucial tool for ensuring healthy embryo selection before implantation.

According to analysis by CMI, the global preimplantation genetic testing market is projected to grow at a CAGR of 7.93% from 2026 to 2034. The market size, valued at USD 936.12 million in 2026, is expected to reach approximately USD 1,863.7 million by 2034. This growth reflects the increasing awareness among prospective parents, advancements in genetic screening technologies, and expanding fertility treatment access worldwide.

Market Overview

Preimplantation genetic testing refers to the genetic analysis of embryos prior to implantation during IVF procedures. It helps identify genetic abnormalities, reducing the risk of inherited diseases and improving pregnancy success rates.

The growing burden of chromosomal abnormalities, delayed parenthood, and rising infertility rates are major factors fueling market demand. Additionally, improvements in diagnostic precision and automation are making PGT more accessible and reliable.

PGT is broadly categorized into:

• Preimplantation Genetic Screening (PGS)

• Preimplantation Genetic Diagnosis (PGD)

These procedures enable clinicians to detect chromosomal aneuploidies and specific genetic mutations, enhancing the likelihood of successful pregnancies.

Market Size and Growth Trends

The steady growth of the PGT market is supported by both technological advancements and demographic trends. Increasing maternal age, particularly in developed economies, has significantly contributed to the demand for genetic screening.

Key growth trends include:

• Increased adoption of IVF procedures globally

• Growing awareness of genetic diseases

• Expansion of fertility clinics and specialized diagnostic centers

• Integration of AI and bioinformatics in genetic testing

Emerging economies are also showing strong growth potential due to improving healthcare infrastructure and rising disposable incomes.

Key Market Drivers

1. Rising Infertility Rates

Infertility has become a global health concern, affecting millions of couples. Lifestyle changes, stress, delayed marriages, and environmental factors are contributing to this trend. PGT provides a reliable solution to improve IVF success rates.

2. Increasing Genetic Disorders

The prevalence of hereditary diseases such as cystic fibrosis, thalassemia, and sickle cell anemia is driving the need for early genetic screening. PGT helps prevent the transmission of such conditions.

3. Technological Advancements

Technologies like Next Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR) have significantly improved the accuracy and speed of genetic analysis. These innovations are enhancing clinical outcomes and boosting market growth.

4. Growing Awareness and Acceptance

Public awareness campaigns and improved healthcare education are encouraging couples to opt for genetic testing. The social acceptance of assisted reproductive technologies is also increasing.

Market Segmentation Analysis

By Procedure

• Preimplantation Genetic Screening (PGS): Widely used for detecting chromosomal abnormalities such as aneuploidy.

• Preimplantation Genetic Diagnosis (PGD): Focuses on identifying specific genetic disorders in embryos.

PGS dominates the market due to its broad application in IVF cycles, while PGD is crucial for families with known genetic risks.

By Product

• Reagents and Consumables: Account for a significant share due to recurring usage.

• Instruments: Include sequencing systems and PCR machines.

• Software: Plays a vital role in data analysis and interpretation.

Reagents and consumables lead the segment due to continuous demand in testing procedures.

By Technology

• Next Generation Sequencing (NGS): Offers high accuracy and scalability, making it the fastest-growing segment.

• Polymerase Chain Reaction (PCR): Widely used for targeted genetic analysis.

• Fluorescent In-Situ Hybridization (FISH): Traditional method, gradually being replaced by advanced techniques.

NGS is expected to dominate the market due to its ability to analyze multiple genetic markers simultaneously.

By Application

• Chromosomal Abnormalities

• X-linked Diseases

• Embryo Testing

• Aneuploidy Screening

• HLA Typing

Aneuploidy screening remains the largest application segment, as it significantly improves IVF success rates.

By End-use

• Fertility Centers

• Hospitals

• Diagnostic Centers

• Research Centers & Academic Labs

Fertility centers hold the largest share, driven by the increasing number of IVF procedures globally.

Regional Analysis

North America

North America dominates the PGT market due to advanced healthcare infrastructure, high adoption of IVF, and strong presence of leading players. The U.S. leads the region with significant investments in genetic research.

Europe

Europe holds a substantial market share, supported by favorable government policies and increasing awareness. Countries like Germany, the UK, and France are key contributors.

Asia-Pacific

Asia-Pacific is expected to witness the fastest growth during the forecast period. Rising infertility rates, expanding healthcare infrastructure, and increasing medical tourism are major factors driving the market in countries like India, China, and Japan.

Rest of the World

Regions such as Latin America and the Middle East are gradually adopting PGT technologies, supported by improving healthcare access and rising awareness.

Competitive Landscape

The preimplantation genetic testing market is highly competitive and characterized by the presence of several global and regional players. Companies are focusing on strategic collaborations, technological innovations, and geographic expansion to strengthen their market position.

Key players in the market include:

• Quest Diagnostics Inc.

• Natera Inc.

• Cooper Surgical Inc.

• Genea Pty Limited

• Invitae Corporation

• Laboratory Corporation of America Holdings

• Thermo Fisher Scientific Inc.

• Bioarray S.L.

• Illumina Inc.

• Igenomix

• RGI

• Hoffmann-La Roche AG

These players are investing heavily in R&D to develop more accurate, faster, and cost-effective testing solutions.

Market Challenges

Despite strong growth prospects, the PGT market faces several challenges:

• High Cost of Procedures: PGT remains expensive, limiting its accessibility in developing regions.

• Ethical Concerns: Genetic testing raises ethical questions regarding embryo selection and genetic modification.

• Regulatory Constraints: Stringent regulations in certain countries may hinder market growth.

• Limited Awareness in Emerging Markets: Lack of education and infrastructure can restrict adoption.

Opportunities

The market presents several growth opportunities:

• Expansion into emerging economies

• Development of cost-effective testing solutions

• Integration of AI and machine learning in genetic analysis

• Increasing partnerships between fertility clinics and diagnostic labs

Advancements in personalized medicine and genomics are expected to further boost the adoption of PGT.

Future Outlook

The future of the preimplantation genetic testing market looks promising, with continuous innovations shaping the industry. The integration of advanced sequencing technologies, automation, and data analytics will enhance diagnostic accuracy and efficiency.

Additionally, the growing trend of delayed parenthood and increasing focus on reproductive health will continue to drive demand. Governments and healthcare organizations are also expected to play a key role in promoting awareness and accessibility.

Conclusion

The global preimplantation genetic testing market is set for significant growth over the forecast period from 2026 to 2034. With a strong CAGR of 7.93%, the market is driven by technological advancements, rising infertility rates, and increasing awareness of genetic disorders.

While challenges such as high costs and ethical concerns persist, ongoing innovations and expanding healthcare access are expected to overcome these barriers. As a result, PGT will continue to play a vital role in modern reproductive medicine, helping ensure healthier pregnancies and improved outcomes for families worldwide.